-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
ADC drugs are currently mainly used in the field of oncology.
Now ADC drugs have entered a hot spot that the industry pays close attention to
.
The industry predicts that the ADC drug field will continue to attract R&D investment, and more good products will appear, providing patients with more choices
.
Drug research and development (picture source: Pharmaceutical Network) In recent years, China has also become popular in the field of ADC drugs
.
At present, there are many domestic companies such as Hengrui Pharmaceutical, CSPC, Kelun Pharmaceutical, Junshi Biological, Zhejiang Pharmaceutical, Fudan Zhangjiang, Lepu Biological, Hausen Pharmaceutical, Biotech, Dongjiao Pharmaceutical, etc.
Xibio and Shanghai Meyac have deployed ADC drugs
.
The author was informed that recently another company claimed to be deploying ADC drug research and development
.
It is understood that on November 2nd, Zhenbaodao issued an announcement stating that it plans to set up a wholly-owned subsidiary in Hangzhou, Zhejiang Province, with a total investment of about 1.
7 billion yuan, invest in the construction of the company’s Hangzhou biopharmaceutical project, engage in the research and development of anti-tumor ADC drugs, and set up other Subsidiaries and other industries
.
The establishment of a wholly-owned subsidiary this time reflects the continued deployment of Zhenbaodao in anti-tumor drugs and biological drugs
.
Public information shows that two anti-tumor chemicals under development on Zhenbao Island have entered the clinical stage, and the target indications cover major cancer types such as liver cancer, stomach cancer, and breast cancer
.
Although China's ADC drug research and development started late, domestic companies have strengthened their layout
.
Among them, Rongchang Bio has attracted much attention, and the company has a variety of ADC drugs
.
It is reported that in June 2021, Rongchang Biotech's Vidicuzumab (RC48) was approved for marketing, becoming the first domestically-made ADC drug
.
It is reported that vedicitumumab will be mainly used for the treatment of gastric tumors
.
In addition, in August 2021, Rongchang Biotechnology and Seagen (Seattle Gene) reached an exclusive global license agreement for the development and commercialization of vedicitumumab.
Seagen will pay a down payment of US$200 million and a milestone payment of US$2.
4 billion to become China High record of overseas authorized transactions of single-variety pharmaceutical companies
.
Currently, there are 3 ADC drugs on the market in China: In addition to the above-mentioned Rongchang Biologics' Vidicituzumab, the other two are Roche's Kadcyla (Enmetrastuzumab), which was approved for marketing in China in January 2020.
(Trade name: Hercelium)); Adcetris (Vebutuximab (trade name: Anshili)) under Takeda Pharmaceuticals approved in China in May 2020
.
The advent of ADC has changed the fate of many drugs, and now it has become a hot spot in the research and development of pharmaceutical companies
.
As of June 2021, there have been 36 new ADC drugs declared for clinical use in China
.
Currently, there are 14 ADC drugs approved for marketing worldwide
.
It is predicted that by 2026, the global market for ADC drugs on the market will reach 16.
4 billion U.
S.
dollars
.
However, some analysts also pointed out that the traditional ADC target track is becoming more and more crowded, and some ADC R&D companies have begun to gradually explore innovative targets.
"This type of target track has not yet formed a clear competition pattern, so there is still great potential for development
.
In In the future, ADC drug patent technology will become the core competitiveness of ADC drug companies
.
” It is understood that in addition to HER2 and other classic targets, the tissue factor antibody drug Tisotumab vedotin jointly developed by Seagen and Genmab has been applied to cervical cancer.
Entered into the third stage (NCT04697628), solid tumor stage 2 (NCT03485209), ovarian cancer stage 2 and so on
.
In China, although ADC drug research and development started late and are still focusing on popular targets, it is believed that with the launch of the first domestic ADC drug Rongchang Bio-RC48, the development of China's ADC drug research and development market will be full of hope in the future, which will also give Domestic patients bring more diversified Chinese->
.
Now ADC drugs have entered a hot spot that the industry pays close attention to
.
The industry predicts that the ADC drug field will continue to attract R&D investment, and more good products will appear, providing patients with more choices
.
Drug research and development (picture source: Pharmaceutical Network) In recent years, China has also become popular in the field of ADC drugs
.
At present, there are many domestic companies such as Hengrui Pharmaceutical, CSPC, Kelun Pharmaceutical, Junshi Biological, Zhejiang Pharmaceutical, Fudan Zhangjiang, Lepu Biological, Hausen Pharmaceutical, Biotech, Dongjiao Pharmaceutical, etc.
Xibio and Shanghai Meyac have deployed ADC drugs
.
The author was informed that recently another company claimed to be deploying ADC drug research and development
.
It is understood that on November 2nd, Zhenbaodao issued an announcement stating that it plans to set up a wholly-owned subsidiary in Hangzhou, Zhejiang Province, with a total investment of about 1.
7 billion yuan, invest in the construction of the company’s Hangzhou biopharmaceutical project, engage in the research and development of anti-tumor ADC drugs, and set up other Subsidiaries and other industries
.
The establishment of a wholly-owned subsidiary this time reflects the continued deployment of Zhenbaodao in anti-tumor drugs and biological drugs
.
Public information shows that two anti-tumor chemicals under development on Zhenbao Island have entered the clinical stage, and the target indications cover major cancer types such as liver cancer, stomach cancer, and breast cancer
.
Although China's ADC drug research and development started late, domestic companies have strengthened their layout
.
Among them, Rongchang Bio has attracted much attention, and the company has a variety of ADC drugs
.
It is reported that in June 2021, Rongchang Biotech's Vidicuzumab (RC48) was approved for marketing, becoming the first domestically-made ADC drug
.
It is reported that vedicitumumab will be mainly used for the treatment of gastric tumors
.
In addition, in August 2021, Rongchang Biotechnology and Seagen (Seattle Gene) reached an exclusive global license agreement for the development and commercialization of vedicitumumab.
Seagen will pay a down payment of US$200 million and a milestone payment of US$2.
4 billion to become China High record of overseas authorized transactions of single-variety pharmaceutical companies
.
Currently, there are 3 ADC drugs on the market in China: In addition to the above-mentioned Rongchang Biologics' Vidicituzumab, the other two are Roche's Kadcyla (Enmetrastuzumab), which was approved for marketing in China in January 2020.
(Trade name: Hercelium)); Adcetris (Vebutuximab (trade name: Anshili)) under Takeda Pharmaceuticals approved in China in May 2020
.
The advent of ADC has changed the fate of many drugs, and now it has become a hot spot in the research and development of pharmaceutical companies
.
As of June 2021, there have been 36 new ADC drugs declared for clinical use in China
.
Currently, there are 14 ADC drugs approved for marketing worldwide
.
It is predicted that by 2026, the global market for ADC drugs on the market will reach 16.
4 billion U.
S.
dollars
.
However, some analysts also pointed out that the traditional ADC target track is becoming more and more crowded, and some ADC R&D companies have begun to gradually explore innovative targets.
"This type of target track has not yet formed a clear competition pattern, so there is still great potential for development
.
In In the future, ADC drug patent technology will become the core competitiveness of ADC drug companies
.
” It is understood that in addition to HER2 and other classic targets, the tissue factor antibody drug Tisotumab vedotin jointly developed by Seagen and Genmab has been applied to cervical cancer.
Entered into the third stage (NCT04697628), solid tumor stage 2 (NCT03485209), ovarian cancer stage 2 and so on
.
In China, although ADC drug research and development started late and are still focusing on popular targets, it is believed that with the launch of the first domestic ADC drug Rongchang Bio-RC48, the development of China's ADC drug research and development market will be full of hope in the future, which will also give Domestic patients bring more diversified Chinese->
.
